DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Simcor (Simvastatin / Niacin) - Published Studies


Simcor Related Published Studies

Well-designed clinical trials related to Simcor (Simvastatin / Niacin)

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. [2010.11.24]

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010.02.15]

Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. [2009.04]

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). [2008.05.15]

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. [2008.04.22]

A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. [2006.06.15]

An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. [2006.01]

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). [2004.02.01]

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). [2003.03.15]

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. [2001.11.29]

Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. [2001.09.28]

Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. [2001.08]

Well-designed clinical trials possibly related to Simcor (Simvastatin / Niacin)

Safety of extended-release niacin/laropiprant in patients with dyslipidemia. [2010.03]

Extended-release niacin (nicotinic acid)/laropiprant. [2009.08.20]

Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. [2009]

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). [2007.06]

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. [2007.03]

[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease] [2004.02]

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. [2003.06.24]

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. [2003.05.01]

Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. [1998.04]

Clinical implications of the biopharmaceutical properties of fluvastatin. [1994.05.26]

Other research related to Simcor (Simvastatin / Niacin)

Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. [2012]

Preparation and evaluation of nicotinic acid sustained-release pellets combined with immediate release simvastatin. [2010.11.15]

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. [2010.11]

Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. [2010.10]

Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. [2010.07.15]

A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. [2010.03]

Niacin extended release (ER)/simvastatin (Simcor(R)): a guide to its use in lipid regulation. [2010]

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. [2010]

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. [2010]

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010]

Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. [2009.04]

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. [2009]

Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. [2008.11]

Safety of niacin and simvastatin combination therapy. [2008.04.17]

Comparison of simvastatin and nicotinic acid administration in alcohol-treated Wistar rats. [2008.03]

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. [2008]

Nelarabine. [2008]

Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin. [2008]

Simvastatin: present and future perspectives. [2007.09]

Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in taiwan. [2006.06]

Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. [2005.09]

Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. [2005.01]

Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data. [2004.05]

Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. [2003.09]

Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. [2003.04]

Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography. [2003.01.01]

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial. [1996.04]

Other possibly related research studies

Fixed-dose combination therapy with statins : strengths, limitations, and clinical and regulatory considerations. [2008]

Do statins reduce events in patients with metabolic syndrome? [2008.02]

Optimal management of combined dyslipidemia: what have we behind statins monotherapy? [2008]

Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia. [2006.01]

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. [2007]

[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors] [2007.01]

Safety of aggressive lipid management. [2007.05.01]

[Effect of hypolipidemic treatment on the composition of bile and the risk or cholesterol gallstone disease] [2007]

Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. [2007.06]

Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. [2006.06]

Use of surrogate measures in cost-effectiveness analyses of lipid-lowering therapies. [1998.09]

[Drug combinations: statins and niacin] [2005.10]

Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. [2005.08.22]

Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. [2005]

Coadministration of multidrug therapy to achieve lipid goals. [2004.09]

Treatment of hyperlipidemia in cardiac transplant recipients. [2004.08]

New perspectives on the use of niacin in the treatment of lipid disorders. [2004.04.12]

Rosuvastatin-induced arrest in progression of renal disease. [2004]

The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. [2004.03]

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. [2003.09]

Pharmacotherapy for dyslipidaemia--current therapies and future agents. [2003.11]

The power of statins: aggressive lipid lowering. [2003.04]

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. [2003.04]

Management of dyslipidemia in the high-risk patient. [2002.12]

Antioxidant vitamins and lipid therapy: end of a long romance? [2002.10.01]

Lipid-lowering drug use and cardiovascular events after myocardial infarction. [2002.05]

The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. [2002.04]

A new reality: achieving cholesterol-lowering goals in clinical practice. [2002.04]

Managing dyslipidemia in the high-risk patient. [2002.03.07]

Randomized clinical trials and recent patterns in the use of statins. [2001.06]

Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. [2000.09]

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. [2000.05.16]

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. [1999.01]

Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. [1998.08]

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. [1998.10]

Peripheral neuropathy and lipid-lowering therapy. [1998.07]

Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. [1997.08]

A review of current clinical findings with fluvastatin. [1996.09.26]

Development and pharmacology of fluvastatin. [1996.01]

Currently available hypolipidaemic drugs and future therapeutic developments. [1995.10]

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. [1995.08.01]

Dyslipidemia and coronary artery disease. [1994.10]

Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. [1993.11]

Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain. [1993.10]

Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. [1990]

Treatment of familial hypercholesterolemia with drugs in children. [1989.01]

Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors. [1989]

Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. [1989.01]

HMG CoA reductase inhibitors. Current clinical experience. [1988]

Treating Hispanic patients for type 2 diabetes mellitus: special considerations. [2008.05]

Gateways to clinical trials. [2008.06]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012